RxDoctor Payments DataLook up a doctor →

Amit Amin, MD

Interventional Cardiology · Lafayette, LANPI 1144458027

Payments from drug & device makers

$81,818in general payments, 2019–2025

Across 677 payments — averaging $120.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$30K
  • Terumo Medical Corporation$12K
  • Penumbra, Inc.$10K
  • Boston Scientific$7K
  • Philips North America LLC$6K
  • Abiomed$5K
  • plus $12K from 53 others

What the payments were for

  • Consulting fees$30,37837%
  • Speaking & faculty fees$12,03515%
  • Travel & lodging$11,87215%
  • Food & beverage$27,53334%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,818 in reported general payments places this provider in the 80th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$836,714
Medicare patients
889
Services billed
5,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban424$361,283
EntrestoSacubitril/Valsartan274$272,650
XareltoRivaroxaban246$214,820
Repatha SureclickEvolocumab117$98,557
FarxigaDapagliflozin Propanediol90$68,008
BrilintaTicagrelor48$46,355
Praluent PenAlirocumab38$34,318
JardianceEmpagliflozin24$17,115
Metoprolol Succinate601$8,085
Rosuvastatin Calcium582$6,112
Atorvastatin Calcium645$5,986
ClopidogrelClopidogrel Bisulfate688$5,983
VascepaIcosapent Ethyl12$5,112
Dabigatran EtexilateDabigatran Etexilate Mesylate24$4,904
Ranolazine ErRanolazine58$3,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$361,283424 claims
NovartisEntresto$381$272,650274 claims
Johnson & JohnsonXarelto$386$214,820246 claims
AstraZenecaFarxiga, Brilinta$116$114,362138 claims
Boehringer IngelheimJardiance$40$17,11524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →